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A B S T R A C T
Human immunodeﬁciency virus type-1 (HIV-1) requires the packaging of human tRNALys3 as a primer for
eﬀective viral reverse transcription. Previously, we reported that glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) suppresses the packaging eﬃciency of tRNALys3. Although the binding of GAPDH to Pr55gag is
important for the suppression mechanism, it remains unclear which domain of GAPDH is responsible for the
interaction with Pr55gag. In this study, we show that Asp256, Lys260, Lys263 and Glu267 of GAPDH are important
for the suppression of tRNALys3 packaging. Yeast two-hybrid analysis demonstrated that the C-terminal domain
of GAPDH (151–335) interacts with both the matrix region (MA; 1–132) and capsid N-terminal domain (CA-
NTD; 133–282). The D256R, K263E or E267R mutation of GAPDH led to the loss of the ability to bind to wild-
type (WT) MA, and the D256R/K260E double mutation of GAPDH resulted in the loss of detectable binding
activity to WT CA-NTD. In contrast, R58E, Q59A or Q63A of MA, and E76R or R82E of CA-NTD abrogated the
interaction with the C-terminal domain of GAPDH. Multiple-substituted GAPDH mutant (D256R/K260E/
K263E/E267R) retained the oligomeric formation with WT GAPDH in HIV-1 producing cells, but the
incorporation level of the hetero-oligomer was decreased in viral particles. Furthermore, the viruses produced
from cells expressing the D256R/K260E/K263E/E267R mutant restored tRNALys3 packaging eﬃciency because
the mutant exerted a dominant negative eﬀect by preventing WT GAPDH from binding to MA and CA-NTD and
improved the reverse transcription. These ﬁndings indicate that the amino acids Asp256, Lys260, Lys263 and
Glu267 of GAPDH is essential for the mechanism of tRNALys3-packaging suppression and the D256R/K260E/
K263E/E267R mutant of GAPDH acts in a dominant negative manner to suppress tRNALys3 packaging.
1. Introduction
It has recently been shown that cellular proteins regulate HIV-1
replication. Interestingly, several studies of puriﬁed HIV-1 virions have
shown that, in addition to proteins encoded by the virus, cellular
proteins are taken into the virions [1]. Some of these proteins, such as
cyclophilin A and lysyl-tRNA synthetase (LysRS), are packaged into
virions as a result of their interaction with Pr55gag or p160gag-pol
proteins during assembly [2–5]. These cellular proteins play an
important role in viral precursor protein folding and tRNALys3 packa-
ging. Thus, understanding the packaging mechanism of cellular
proteins is one way to elucidate the viral replication capacity.
One of the critical events in HIV-1 replication is reverse transcrip-
tion. Cellular tRNALys3 is required for the eﬃcient initiation of reverse
transcription and is selectively incorporated into viral particles during
its assembly because the 3′ terminal 18 nucleotides must be hybridized
to the primer-binding site of HIV-1 genome RNA as a replication
primer [6]. Gabor et al. [7] reported that the elevated amount of
packaged tRNALys3 increases viral infectivity. Eﬃcient packaging of
tRNALys3 is facilitated by interaction between Pr55gag or p160gag-pol
and LysRS, which act as carriers of tRNALys3 [8,9].
Although GAPDH was initially identiﬁed as a glycolytic enzyme, it
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has been known as a “moonlighting” protein. Several studies have
shown that GAPDH is related to apoptosis, the exportation of nuclear
RNA, and DNA repair. [10]. Furthermore, GAPDH regulates viral
replication by binding to cis-acting viral RNAs, such as the hepatitis A
virus, hepatitis C virus and human parainﬂuenza virus [11–13].
Similarly, we previously reported that GAPDH also plays a role in
negatively regulating HIV-1 infection [14]. GAPDH is incorporated into
virions via its interaction with Pr55gag [14]. Increased GAPDH
packaging eﬃciency decreases reverse transcription eﬃciency owing
to the suppression of LysRS and tRNALys3 packaging [14]. Thus, the
binding of GAPDH to Pr55gag has an important role in the suppres-
sion of HIV-1 replication. These ﬁndings indicate that GAPDH
negatively regulates HIV-1 replication and provide insights into a
new host defense mechanism against HIV-1 infection. However, it is
remains unclear which amino acid residues of GAPDH are important
for the recognition of Pr55gag.
In this study, we show that amino acids Asp256, Lys260, Lys263 and
Glu267 of GAPDH interact with MA and CA-NTD domain of Pr55gag
and the D256R/K260E/K263E/E267R mutant of GAPDH acts as a
dominant negative inhibitor of tRNALys3 packaging. These ﬁndings
provide a new insight into tRNALys3 packaging mechanism and indicate
a novel regulatory step of HIV-1 replication.
2. Materials and methods
2.1. Cell culture
TZM-bl cells, which were obtained from the NIH AIDS Research
and Reference Reagent Program, and HEK293 cells were maintained at
37 °C in DMEM supplemented with 10% fetal calf serum (FCS)
containing 100 IU/ml penicillin and 100 μg/ml streptomycin in 5%
CO2.
2.2. Viruses
The infectious molecular clone pNL-CH [15], derived from the
pNL4-3 clone of HIV-1, and each mutated GAPDH expression vector
(cloned into the pcDNA3.1D/V5-His-TOPO® vector) were cotransfected
into HEK293 cells to prepare various GAPDH-mutant-packaging
viruses. At 48 h post-cotransfection, the virus-containing supernatant
was collected and clariﬁed by ﬁltration using 0.45-µm-pore-size ﬁlters
[14].
2.3. Plasmid
The coding region of the HIV-1NL-CH protein and GAPDH was
ampliﬁed by PCR using the following primers. Pr55gag: Pr55gag UP
(5′-AGAATTCATGGGTGCGAGAGCGTCGGTATTA-3′) and Pr55gag DN
(5′-TGGATCCTTATTGTGACGAGGGGTCGCTGCC-3′); MA: Pr55gag UP
and MA DN (5′-TGGATCCTTAGTAATTTTGGCTGACCTG-3′); CA: CA
UP (5′-AGAATTCCCTATAGTGCAGAACCTCCAG-3′) and CA DN (5′-
TGGATCCTTACAAAACTCTTGCTTTATGGCC-3′); CA-NTD: CA UP and
CA-NTD DN (5′-TGGATCCTTAAATGCTGGTAGGGCTATACAT-3′); CA-
CTD: CA-CTD UP (5′-AGAATTCCTGGACATAAGACAAGGACCA-3′) and
CA DN; NC: NC UP (5′-AGAATTCATACAGAAAGGCAATTTTAGG-3′)
and NC DN (5′-TGGATCCTTAATTAGCCTGTCTCTCAGTACA-3′); p6: p6
UP (5′-AGAATTCCTTCAGAGCAGACCAGAGCCA-3′) and Pr55gag DN;
p160gag-pol: p160gag-pol UP (5′-ACTAGTCATATGGATGAATTCATG-
GGTGCGAGAGCGTCGGTATTA-3′) and p160gag-pol DN (5′-ACCC-
GGGGATCCGATGGATCCTTAATCCTCATCCTGTCTACTTGC-3′); Pol:
Pol UP (5′-GGAGGCCAGTGAATTCCCTCAGATCACTCTTTGGCAG-3′)
and p160gag-pol DN; GAPDH: GAPDH UP (5′-AGAATTCATGGGGAA-
GGTGAAGGTCGGAGTCAAC-3′) and GAPDH DN (5′-TGGATCCTTA-
CTCCTTGGAGGCCATGTGGGC-3′); GAPDH-n: GAPDH UP and GAP-
DH-n DN (5′-TGGATCCTTAGCAGGAGGCATTGCTGAT-3′); GAPDH-c:
GAPDH-c UP (5′-AGAATTCTCCTGCACCACCAACTGCTTA-3′) and
GAPDH DN. For the yeast-two-hybrid (Y2H) analysis, the HIV-1 protein
or GAPDH coding regions were cloned into the EcoRI and BamHI sites of
pGBKT7 or pGADT7, respectively (Clontech Laboratories, Inc.). The full-
length GAPDH coding regions were also cloned into the EcoRV and
BamHI sites of the pcDNA™ 3.1D/V5-His-TOPO® vector (Thermo Fisher
Scientiﬁc, Inc.). Each mutated GAPDH construct was obtained by site-
directed mutagenesis. All of the mutations were veriﬁed by sequencing.
2.4. Yeast two-hybrid analysis
The Matchmaker™ Gold Yeast Two-hybrid System (Clontech
Laboratories, Inc.) was used in accordance with manufacturer's
recommendations to analyze the interaction between several recon-
structed GAPDH and HIV-1 proteins. Brieﬂy, the bait (cloned into
pGBKT7) and prey (cloned into pGADT7) constructs were cotrans-
formed into Y2HGold and plated on QDO/X/A plates (without
tryptophan leucine, adenine, and histidine and with aureobasidin A
and X-α-Gal). As a positive or negative control, pGADT7-T and
pGBKT7-53 or pGADT7 AD and pGBKT7 DNA-BD were cotrans-
formed, respectively. To validate transformed protein expression, each
yeast strain was lysed and detected using an anti-HA antibody (Wako
Pure Chemical Industries, Ltd.) or an anti-c-Myc antibody (Clontech
Laboratories, Inc.).
2.5. Coimmunoprecipitation
HEK293 cells transfected with each GAPDH expression vector were
lysed and the lysate was used for coimmunoprecipitation, as a
previously described [14]. Brieﬂy, the precleaned lysate was incubated
with an anti-V5 antibody (Thermo Fisher Scientiﬁc Inc.) or an isotype
control mouse IgG antibody (R &D SYSTEMS, Inc.), and further
incubated with µMACS™ Protein G MicroBeads (Miltenyi Biotec
K.K.). The separated proteins were detected by western immunoblot
analysis using the anti-GAPDH antibody (Santa Cruz Biotechnology,
Inc.). To detect GAPDH interacting Pr55gag, pNL-CH and WT or M6
GAPDH expression vector were cotransfected into HEK293 and the
resulting lysate was incubated with an anti-GAPDH antibody before
incubating with µMACS™ Protein G MicroBeads.
2.6. Measurement of tRNALys3 packaging levels in virions and
reverse transcription products
tRNALys3 was prepared from various GAPDH mutants packaging
viruses, as a previously described [14]. Brieﬂy, tRNALys3 was collected
from each virus and reverse-transcribed using a SuperScript™ III First-
strand Synthesis System (Thermo Fisher Scientiﬁc, Inc.). The packa-
ging level of tRNALys3 was normalized by incorporated viral genomic
RNA. The reverse transcription products were analyzed using pre-
viously described methods [14]. Total DNA from each virus infected
TZM-bl cells was subjected to quantitative real-time PCR with primer
pair speciﬁc for the R/U5 (early) region.
3. Results
3.1. C-terminal domain of GAPDH interacts with HIV-1 MA and CA
We previously demonstrated that GAPDH, which is expressed in
HIV-1 producer cells, is incorporated into viral particles via its
interaction with viral precursor proteins [14]. To further investigate
which domain is required for the interactions, we prepared viral
proteins- or GAPDH-expression vectors, and performed Y2H analysis.
The Y2HGold yeast strain was cotransformed with the constructed bait
(Fig. 1A) and prey (Fig. 1B) vectors and grown on the QDO/X/A plates.
As shown in Fig. 1C, the growth of blue colonies on the QDO/X/A
plates signiﬁes the positive interaction between the C-terminal domain
of GAPDH (GAPDH-c) and Pr55gag. Furthermore, Y2H analysis using
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processing forms of Pr55gag indicated that MA and CA-NTD interact
with GAPDH-c. In contrast, the Y2HGold yeast strain cotransformed
with GAPDH-c and p160gag-pol did not grow on the QDO/X/A plates,
despite suﬃcient protein expression levels, because the GAL4-activa-
tion domain (GAL4 AD) fused to p160gag-pol could not translocate to
the nucleus [16]. Although the p6 bait protein also indicated positive
interaction with GAPDH-c, this result reﬂected its autoactivity, which
was conﬁrmed by transforming only the bait vector into Y2HGold in
the absence of the prey vector (Supplementary Fig. 1). These results
suggest that MA and CA-NTD are essential for speciﬁc binding via the
multiple-site binding of GAPDH to Pr55gag.
3.2. Asp256, Lys263 and Glu267 of GAPDH interact with HIV-1 MA and
Asp256 and Lys260 of GAPDH are essential for the interaction between
GAPDH and CA-NTD
To explore the MA- or CA-NTD-interacting domain of GAPDH, we
performed docking simulation of interaction between GAPDH (PDB
ID: 1ZNQ) [17] and MA (PDB ID: 2H3I) [18] or CA (PDB ID: 1E6J)
[19] with a software system molecular operating environment (MOE)-
Dock (Docking software). The docking simulation proposed one
possible model that the GAPDH helix 10 (255–267), which is located
at the surface of GAPDH, plays a role in the interaction between
GAPDH-c and MA or CA-NTD (Fig. 2A). Because GAPDH actually
exists as a stable tetramer, which is in equilibrium with a metastable
dimer, it is possible that GAPDH tetramer interacts with more than two
proteins using same region. Therefore, on the basis of these deduced
interaction domains, 5 single-point and 5 multiple-point mutants of
the helix 10 domain of GAPDH were prepared to perform mutagenesis
study (Fig. 2B).
In Y2H analysis using GAPDH mutants and WT MA, as shown in
the Fig. 3A, the K260E and Q264A of GAPDH mutants retained their
ability to interact with WT MA. In contrast, the D256R, K263E or
E267R of GAPDH mutants showed the loss of the ability to bind to WT
MA. In addition, combined mutations except for D256R/K260E (M1)
caused the loss of interaction. Western immunoblot analysis indicated
that these eﬀects were apparently not due to the low expression levels
of the bait and prey proteins (Fig. 3B). On the other hand, the docking
simulation predicted that residues Arg58, Gln59 and Gln63 of MA
formed an ion or a hydrogen bond network with Asp256, Lys263 and
Glu267 of GAPDH. As shown in the Fig. 3C, the R58E, Q59A and Q63A
of MA mutants did not interact with GAPDH-c. These eﬀects were also
Fig. 1. Y2H analysis of interaction between GAPDH and HIV-1 precursor proteins. (A) Bait constructs obtained from pNL-CH and (B) prey constructs obtained from human GAPDH
are illustrated. (C) Y2H analysis of N-terminal domain of GAPDH (GAPDH-n) or C-terminal domain of GAPDH (GAPDH-c) with p160gag-pol, Pr55gag, MA, CA, CA-NTD, CA-CTD,
NC, p6 or Pol. The Y2HGold strain was cotransformed with the constructs-expressing bait (as indicated in Fig. 1A) and prey proteins (as indicated in Fig. 1B). Growth on QDO/X/A
plates indicates the positive interaction.
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not due to the low protein expression levels of the bait and prey
proteins (Fig. 3D). These ﬁndings suggest that Asp256, Lys263 and
Glu267 of GAPDH are crucial for the interaction between GAPDH and
MA.
Since the docking simulation proposed that GAPDH helix 10 is also
required for the interaction with CA-NTD, Y2H analysis focusing on the
interaction GAPDH and CA-NTD was carried out. The D256R, K260E,
K263E, Q264A and E267R of GAPDH single-point mutants maintained
the interaction between GAPDH and CA-NTD (Fig. 3E). In contrast,
the multiple-point mutations of GAPDH, D256R/K260E (M1), D256R/
K260E/Q264A (M3) and D256R/K260E/Q264A/E267R (M5) lacked
the binding ability to the WT CA-NTD. These results suggest that both
of Asp256 and Lys260 of GAPDH play an important role in GAPDH
interaction with CA-NTD. Furthermore, the docking simulation pre-
dicted that Asp256 and Lys260 of GAPDH interact with Arg82, Glu79 and
Glu76 of CA-NTD. Therefore, we prepared the E76R, E79R and R82E of
CA-NTD mutants and coexpressed them with GAPDH-c. As shown in
the Fig. 3G, the E79R of CA-NTD mutant retained its ability to interact,
but the E76R and R82E mutants lost their ability to interact with
GAPDH-c. These eﬀects were apparently not due to the low expression
levels of the bait and prey proteins (Fig. 3F and H). These results
suggest that GAPDH-c requires Asp256 and Lys260 to bind to CA-NTD.
3.3. Asp256, Lys260, Lys263 and Glu267 of GAPDH are critical residues
for tRNALys3-packaging suppression eﬀect
The Y2H analysis demonstrated that GAPDH helix 10 contributes
to the interaction of GAPDH with both MA and CA-NTD. Because MA
and CA exist as the precursor protein Pr55gag in HIV-1 producer cells,
we next prepared the D256R/K260E/K263E/E267R mutant (M6) of
GAPDH (Fig. 4A). To examine whether M6 GAPDH interacts with WT
Pr55gag, M6 GAPDH and Pr55gag were coexpressed in the Y2HGold
strain. M6 GAPDH did not show interaction with WT Pr55gag, MA or
CA-NTD (Fig. 4B, left panel), despite the expression levels being
suﬃcient for examining protein-protein interaction (Fig. 4B, right
Fig. 2. Deduced interaction between GAPDH and MA or CA. (A) Proposed models for the interaction of GAPDH with MA (left) or CA (right). (B) GAPDH constructs mutated in
GAPDH-c in Y2H analysis.
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panel), suggesting that Asp256, Lys260, Lys263 and Glu267 of GAPDH are
important for the interaction between GAPDH and Pr55gag.
We previously reported that viruses produced from GAPDH-over-
expressing cells enhanced GAPDH packaging and suppressed tRNALys3
packaging [14]. Therefore, V5-tagged WT or M6 GAPDH expression
vectors were prepared and cotransfected into HEK293 cells with pNL-
CH to investigate whether the viruses produced from M6-GAPDH-
expressing cells showed suppressed GAPDH packaging and restored
tRNALys3 packaging eﬃciency. We ﬁrst performed coimmunoprecipita-
tion assay to validate whether endogenous GAPDH and exogenous V5-
tagged GAPDH retained oligomatic formation, because GAPDH exists
primarily as a homotetramer in the cytoplasm [17]. The assay showed
that both V5-tagged WT and M6 GAPDH retained oligomatic forma-
tion with endogenous GAPDH in HIV-1 producer cells (Fig. 4C),
suggesting that M6 did not aﬀect the oligomatic formation of
GAPDH. Furthermore, overexpression of V5-tagged WT GAPDH in
HIV-1 producer cells (Fig. 4D, WT lane of producer cells) increased the
endogenous and V5-tagged WT GAPDH incorporation levels in viruses
(Fig. 4D, WT lane of viral particles) as previously described [14].
However, as expected, a similar level of expression of M6 GAPDH
(Fig. 4D, M6 lane of producer cells) decreased the incorporation levels
of both endogenous and V5-tagged M6 GAPDH (Fig. 4D, M6 lane of
viral particles) in comparison with that of WT GAPDH. To address
whether the decreased incorporation level of V5-tagged M6 GAPDH
depended on the poorer interaction of GAPDH with Pr55gag than V5-
tagged WT GAPDH, we examined the interaction level in the virus
Fig. 3. Y2H analysis of the interaction between C-terminal domain of GAPDH (GAPDH-c) and MA or CA-NTD. (A) The C-terminal domain of WT or GAPDHmutants was used as prey
proteins, and WT MA was used as the bait protein. (B) Bait and prey proteins expression level in Y2HGold strain using Fig. 3A. (C) WT or MA mutants were used as bait proteins, and
WT GAPDH-c was used as the prey protein. (D) Bait and prey proteins expression level in Y2HGold strain using Fig. 3C. (E) The C-terminal domain of WT or GAPDH mutants was used
as prey proteins, and WT CA-NTD was used as the bait protein. (F) Bait and prey proteins expression level in Y2HGold strain using Fig. 3E. (G) WT or CA-NTD mutants were used as
bait proteins, and WT GAPDH-c was used as the prey protein. (H) Bait and prey proteins expression level in Y2HGold strain using Fig. 3G. Western immunoblot analysis of total protein
extracts from each transformed Y2HGold strain was performed using the anti-HA antibody (against prey proteins) and the anti-c-Myc antibody (against bait proteins), respectively.
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producer cells by coimmunoprecipitation assay. As a result, the
interaction between oligomatic GAPDH, which was composed of
endogenous GAPDH and V5-tagged WT or M6 GAPDH, and Pr55gag
was found to be weaker in V5-tagged M6 GAPDH-expressing cells
(Fig. 4E, M6 lane of IP) than in V5-tagged WT GAPDH-expressing cells
(Fig. 4E, WT lane of IP). This ﬁnding suggests that the amino acid
residues Asp256, Lys260, Lys263 and Glu267 of GAPDH play critical roles
in the interaction of GAPDH with Pr55gag and GAPDH packaging into
virions. Finally, we examined the eﬀects of M6 GAPDH on the viral
replication by measuring tRNALys3 packaging level and reverse tran-
scription products. Although the expression of WT GAPDH suppressed
packaging of tRNALys3 as previously described, the expression of M6
GAPDH rescued packaging of tRNALys3 (Fig. 4F). Furthermore, the
levels of early reverse transcription products were also recovered by M6
GAPDH expression in virus producer cells (Fig. 4G). These ﬁndings
indicate that the Asp256, Lys260, Lys263 and Glu267 residues within
GAPDH are critical for the mechanism of tRNALys3-packaging suppres-
sion and that M6 GAPDH acts as a dominant negative regulator of
Fig. 4. Eﬀect of mutations of Asp256, Lys260, Lys263 and Glu267 in GAPDH on HIV-1 replication. (A) To validate the critical residues of GAPDH, D256R/K260E/K263E/E267R
mutation (M6) was introduced in GAPDH. (B) Y2H analysis of interaction between M6 GAPDH and MA or CA-NTD. The M6 GAPDH prey and MA or CA-NTD bait vector were
cotransfected into Y2HGold. M6 GAPDH abrogated the GAPDH interaction with MA and CA-NTD (left panel), although each protein was expressed (right panel). (C)
Coimmunoprecipitation assay of endogenous and exogenous GAPDH (V5-tagged WT or M6 GAPDH). (D) GAPDH expression in HIV-1 producer cells and incorporation level of
GAPDH in viral particles. V5-tagged WT or M6 GAPDH was used to distinguish between endogenous and exogenous GAPDH. HEK293 cells were cotransfected with pNL-CH and V5-
tagged WT, M6 GAPDH or empty (indicated as control) expression vector. Pr55gag and p24 were detected by HIV-1-positive plasma (HPP). (E) Coimmunoprecipitation assay of
GAPDH and Pr55gag. (F) Packaging level of tRNALys3. The amount of tRNALys3 in the control virus was set as 100%. (G) Eﬀects of each virus that is produced from cells transfected with
WT or M6 GAPDH vector on early reverse transcription products in TZM-bl cells. The value in the control experiment was set as a 100%. The signiﬁcance of diﬀerence (Nonrepeated
measures ANOVA and Dunnett's test versus WT) is indicated as follows: **, p < 0.01; *, p < 0.05. The error bars denote the standard deviation. The mean values of at least three
independent experiments are shown.




During HIV-1 assembly, the selective cellular tRNALys3 packaging is
required for the eﬀective reverse transcription [6]. Thus, the disruption
of the interaction between the Pr55gag/p160gag-pol/viral genome
RNA complex and the tRNALys3/LysRS complex likely provides a novel
therapeutic strategy. Interestingly, we previously identiﬁed cellular
GAPDH inside virions as a tRNALys3 packaging inhibitor and demon-
strated that the inhibitory mechanism is dependent on the interaction
between cellular GAPDH and HIV-1 precursor proteins (Pr55gag and
p160gag-pol) [14]. However, it remained unclear how GAPDH inter-
acts with these proteins. Our ﬁndings indicate that tRNALys3 packaging
is interrupted by the interaction of GAPDH with MA and CA-NTD
translated as part of viral precursor proteins. The GAPDH mutagenesis
assay indicated that Asp256, Lys260, Lys263 and Glu267 of GAPDH are
important residues in the interaction of GAPDH with MA and CA-NTD.
Importantly, the crystal structure of GAPDH tetramer (PDB ID: 1ZNQ)
[17] shows that all of these amino acids in helix 10 are exposed on four
each of monomer GAPDH, suggesting that two subunits of the GAPDH
tetramer simultaneously interact with MA and CA-NTD, respectively
(Supplementary Fig. 2A and B). On the other hand, Y2H analysis
demonstrated that the R58E, Q59A or Q63A of MA, and E76R or R82E
of CA-NTD mutants abrogated their interaction with the C-terminal
domain of GAPDH. MA (Arg58, Gln59 and Gln63) or CA (Glu76 and
Arg82) residues, which contribute to ionic or hydrogen bond interaction
with Asp256, Lys260, Lys263and Glu267 of GAPDH, are also exposed on
the surface of MA or CA and located on the same side of MA helix 3 or
CA helix 4 (Supplementary Fig. 2A). Interestingly, a MOE candidate
model (Fig. 2A) conferred a somewhat diﬀerent helix orientation
between GAPDH-MA or GAPDH-CA-NTD (Supplementary Fig. 2C)
and was supported by Y2H analysis and data regarding oligomatic
formation, tRNALys3 packaging level and reverse transcription using
M6 GAPDH. Furthermore, we tried to prepare mutant pNL-CH
proviral clones encoding R58E/Q59A/Q63A in MA and E76R/R82E
in CA to clarify the eﬀects of these mutations on tRNALys3 incorpora-
tion. The mutated pNL-CH expressed a similar level of the virus
precursor protein in HIV-1 producer cells to WT pNL-CH. However, we
did not examine whether the tRNALys3 incorporation level inside
virions was increased because the mutational introduction within the
capsid-coding gene (E76R, R82E) impaired HIV-1 budding (data not
shown).
Many studies have denoted how tRNALys3 is incorporated into
virions. The ﬁndings of such studies demonstrated that the tRNALys3/
LysRS complex interacts with the Pr55gag/p160gag-pol/viral genome
RNA complex and is eﬃciently packaged into virions [4,5,9,20,21].
Javanbakht et al. [5] demonstrated that the domains critical for the
Pr55gag-LysRS interaction are mapped to include the dimerization
domains of both LysRS and CA. Kovaleski et al. [20] more speciﬁcally
reported that the interaction between LysRS and Pr55gag is dependent
on the helix 7 of LysRS and the helix 4 of CA-CTD of Pr55gag. In
addition, Khorchid et al. [21] reported that the interaction between
tRNALys3 and p160gag-pol is involved in the thumb domain sequence
of reverse transcriptase (RT). However, the amounts of all tRNALyss
(tRNALys1,2 and tRNALys3) and non-tRNALyss incorporated into virions
are signiﬁcantly increased when p160gag-pol is present with Pr55gag
[22]. Thus, Kleiman et al. [23] reviewed that p160gag-pol probably
increases the incorporation of all tRNAs into Pr55gag virus-like
particles through the nonspeciﬁc binding of tRNAs to RT sequences
within p160gag-pol. Since there is no evidence that RT sequences in
p160gag-pol show a preference for interacting with tRNALys3 and not
with other tRNAs, Pr55gag does speciﬁcally interact with LysRS to play
an important role in concentrating tRNALys3 in the virions. These
ﬁndings suggest that by sterically inhibiting the interaction between the
Pr55gag and tRNALys3/LysRS complex, the GAPDH tetramer eﬃ-
ciently suppresses the incorporation of tRNALys3 into the virions.
Taken together, these ﬁndings indicate that increasing the stability of
the GAPDH tetramer or shifting the equilibrium toward the tetramer
by increasing the expression level of GAPDH in HIV-1-infected cells
might provide an eﬀective approach to interrupt the tRNALys3 packa-
ging into virions.
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